[
  {
    "ts": "2026-01-10T02:10:48+00:00",
    "headline": "How The Vertex Pharmaceuticals (VRTX) Story Is Shifting With New Analyst Targets And CF Outlook",
    "summary": "Why the Vertex Price Target Just Got Tweaked The small lift in Vertex Pharmaceuticals' fair value estimate to US$496.16 per share, alongside a slightly higher discount rate and a touch stronger long range revenue growth assumption, reflects how recent Street commentary is reshaping the story around the stock. Analysts pointing to the durability of the cystic fibrosis franchise through at least 2037 and the breadth of the broader pipeline are feeding updated models that lean a bit more...",
    "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-story-shifting-021048149.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "8c4b5a9b-b734-3591-84b7-810a6b969e3e",
      "content": {
        "id": "8c4b5a9b-b734-3591-84b7-810a6b969e3e",
        "contentType": "STORY",
        "title": "How The Vertex Pharmaceuticals (VRTX) Story Is Shifting With New Analyst Targets And CF Outlook",
        "description": "",
        "summary": "Why the Vertex Price Target Just Got Tweaked The small lift in Vertex Pharmaceuticals' fair value estimate to US$496.16 per share, alongside a slightly higher discount rate and a touch stronger long range revenue growth assumption, reflects how recent Street commentary is reshaping the story around the stock. Analysts pointing to the durability of the cystic fibrosis franchise through at least 2037 and the breadth of the broader pipeline are feeding updated models that lean a bit more...",
        "pubDate": "2026-01-10T02:10:48Z",
        "displayTime": "2026-01-10T02:10:48Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ihFoSuY9PLXURl2kI_sV.w--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bIz6sh0rX4c7ACsVP8z51w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/be31617c737d47553e0bc442fa8fa6d9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-story-shifting-021048149.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/vertex-pharmaceuticals-vrtx-story-shifting-021048149.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VRTX"
            },
            {
              "symbol": "WSFX.BO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]